GEN Exclusives

More »

GEN News Highlights

More »
Apr 4, 2008

Raven and Bioprocessing Technology Institute Partner on Stem Cell Antibody Discovery

  • Raven biotechnologies and the Bioprocessing Technology Institute (BTI) agreed to work together to advance the discovery of cancer stem-cell antibodies.

    Raven will license its whole-cell immunization technology for use with BTI's stem cells. Raven will screen the resulting antibodies against its collection of cancer lines including its cancer stem-cell lines.

    Raven will own rights to antibodies BTI generates through this partnership for use in cancer therapeutics and diagnostics. BTI will retain rights to antibodies for all other indications.

    “Both BTI and Raven have much to gain from this strategic alliance,” says Miranda Yap, Ph.D., executive director of BTI. “It will help strengthen our respective fields of research and advance science to better human healthcare. Generation of these novel antibodies to stem cells with Raven's proprietary technology will enable the development of tools for the characterization of stem cells, and importantly, these antibodies will also be valuable for the separation of stem-cell populations for BTI's cell-therapy work.”



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?